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OBJECTIVE: Orofacial granulomatosis (OFG) is a rare
condition characterized by non-caseating granulomas in
the orofacial region. Protease-Activated Receptors
(PARs) play a role in inflammatory diseases in diverse
human tissues. The aim of the study was to investigate
the expression of PAR-1, PAR-2, MMP-2, MMP-9, COX-1,
and COX-2 in tissues taken from OFG patients.
METHODS: PAR-1, PAR-2, MMP-2, MMP-9, COX-1,
and COX-2 expression was evaluated by im-
munohistochemistry in biopsies taken from oral Crohn’s
disease (five cases), Melkersson–Rosenthal syndrome
(MRS) (six cases), cheilitis granulomatosa (five cases) and
normal oral mucosa (five cases).
RESULTS: PAR-1 was observed in mononuclear in-
flammatory cells in edematous/lichenoid lesions, whereas
a strong PAR-2 immunostaining was detected in epithe-
lioid histiocytes and giant cells in granulomatous lesions,
irrespective of the clinical features (Crohn vsMRS). MMPs
and COX-2 were expressed in the inflammatory com-
ponent of edematous/lichenoid lesions and markedly
overexpressed in granulomatous lesions. COX-1 was
weakly and variably expressed in both edematous/
lichenoid and granulomatous lesions.
CONCLUSION: Thus,PAR-1andPAR-2expressionswere
related to the intensity and type of inflammatory response
but not to the type of clinical lesion. Simultaneous over-
expression of PARs, MMPs and COXs suggests synergism
among these proinflammatory receptors and enzymes.
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Introduction
The term orofacial granulomatosis’ (OFG) was origin-
ally introduced to encompass a broad spectrum of
non-caseating granulomatous inflammatory conditions,
affecting the oral and maxillo-facial region, including
Melkersson–Rosenthal syndrome (MRS), cheilitis
granulomatosa (CG), sarcoidosis, oral Crohn’s disease
(OCD) and some infectious disorders (Weisenfeld et al,
1985; Ficarra et al, 1993; van der Waal et al, 2002).
More recently, the term OFG has been more restric-
tively used to indicate only the idiopathic forms, e.g.
MRS and CG (Mignogna et al, 2003; Sciubba and
Said-Al-Naief, 2003), thereby excluding oral granulo-
matous inflammation because of systemic or local
diseases (Crohn’s disease, sarcoidosis, infectious disor-
ders, foreign body reactions and food and contact
allergies). Patients with MRS only occasionally (8–25%)
express the classical clinical triad of orofacial swelling,
fissured tongue and facial paralysis (Sciubba and
Said-Al-Naief, 2003). More commonly, MRS has a
mono-symptomatic or oligo-symptomatic clinical pre-
sentation (Daoud and Rogers, 1995; Rogers, 1996;
Sciubba and Said-Al-Naief, 2003). CG is a monosymp-
tomatic form of MRS and is clinically characterized by
persistent, painless labial enlargement (Rogers, 1996;
Sciubba and Said-Al-Naief, 2003).
Review of the literature shows that the relationship
between OCD and OFG is a more controversial and still
unresolved issue, as there have been reports of OFG
being the initial presentation of OCD, as well as many
examples of OCD eventually developing bowel involve-
ment (Girlich et al, 2002; Bogenrieder et al, 2003; van de
Scheur et al, 2003; Lea˜o et al, 2004). Hence, classifica-
tion and management of OFG patients requires routine
investigations in search of possible gastrointestinal
involvement.
Recently, considerable interest has been paid to the
role of protease-activated receptors (PARs) in patho-
physiology. PARs are a novel family of the G-protein
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coupled receptors that require proteolytic cleavage of
their amino-terminal domain to be activated (MacFar-
lane et al, 2001; Ossovskaya and Bunnett, 2004). There
is evidence that PAR-1, which is activated by thrombin
and PAR-2, which is activated by trypsin, mast cell
tryptase and coagulation factors, have a crucial role in
inflammatory diseases of diverse tissues, including the
gut, skin and airways (MacFarlane et al, 2001; Ossovs-
kaya and Bunnett, 2004). In particular, a possible role of
PAR-2 in a rat model of periodontitis involving also
prostaglandin release and MMP-2 and MMP-9 activa-
tion has been reported (Holzhausen et al, 2005).
However, no information regarding the distribution
and possible role of PARs has been reported in acute or
chronic inflammatory conditions of the human oral
cavity. The aim of the study was to explore a possible
role of PAR-1 and PAR-2 and related bioactive
mediators (MMP-2, MMP-9, COX-1, COX-2) in OFG.
Materials and methods
Patients selection
Eighteen patients with OFG were retrospectively identi-
fied from the files of the Department of Odontostoma-
tology of the University of Florence and the
Department of Dentistry and Surgery of the University
of Bari. The series included patients with OCD (seven
cases), MRS (six cases), CG (five cases). There were
eight women and 10 men. The median age of the
patients with OCD was 17 years (range 7–79 years). The
median age of the patients with MRS was 49.5 (range
27–67 years). The median age of the patients with CG
was 49.4 (range 35–62 years). Upon histopathological
revision, two cases of OCD and one case of CG were
excluded for inadequate biopsy material and/or clinical
data. Therefore, the immunohistochemical investiga-
tions were performed on 13 out of 15 remaining cases
(five OCD, five MRS and three CG) as well as five cases
of normal oral mucosa, taken as control.
Immunohistochemistry
Sections 4 lm in thickness were cut from tissue blocks of
formalin-fixed paraffin-embedded tissues. All sections
were deparaffinized in Bio-Clear (Bio Optica, Milan,
Italy) and dehydrated using graded ethanol. To block
endogenous peroxidase activity, the slides were treated
with 3.0% hydrogen peroxidase in distilled water for
10 min. Antibodies included: anti-PAR-1 (mouse mono-
clonal antibody, clone ATAP 2; Zymed laboratories
Inc., South San Francisco, CA, USA); anti-PAR-2
(mouse monoclonal antibody, clone SAM 11; Zymed);
anti-MMP-2 (mouse monoclonal antibody, clone 42–
5D11; Oncogene research products, Cambridge, MA,
USA); anti MMP-9 (mouse monoclonal antibody, clone
56–2A4; Oncogene research products); anti-COX-1
(mouse monoclonal antibody, clone COX 111; Zymed);
anti-COX-2 (mouse monoclonal antibody, clone COX
229; Zymed).
Antigen retrieval was routinely performed by micro-
wave pretreatment (Microwave MicroMED T/T Mega;
Milestone, Bergamo, Italy) in TEC (Tris-EDTA-citrate
buffer pH 7.8) for 35 min. After blocking non-specific
antigen with normal horse serum (UltraVision, LabVi-
sion, Fremont, CA, USA), the sections were incubated
with the primary antibodies diluted in Antibody Diluent
(Ventana Medical Systems, Tucson, AZ, USA): (i) anti-
PAR-1 and PAR-2 diluted 1:50, and incubated for 1 h at
room temperature (RT); (ii) anti-MMP-2 and anti-
MMP-9 diluted 1:10, and incubated for 1 h at RT; (iii)
anti-COX-1 and anti-COX-2 diluted 1:50, and incu-
bated for 2 h at RT. Staining was carried out using a
biotin-conjugated anti-rabbit/anti-mouse secondary
antibody (Ultra Vision) and streptavidin-peroxidase
(Ultra Vision). The bound antibodies were visualized
using 3.3¢ diaminobenzidine (DAB, BioGenex, San
Roman, CA, USA) and aminoethylcarbazol (AEC;
LabVision) as chromogen for PARs and diaminobenzi-
dine for MMPs and COXs. Nuclei were lightly counter-
stained with Mayer’s hematoxylin. Negative controls
were performed by substituting the primary antibody
with a non-immune serum at the same concentration.
Control sections were treated in parallel with the
samples in the same run.
Immunostained sections were independently assessed
by three observers (S.K., D.M., M.S.) and the results
were expressed according to semiquantitative criteria as
negative staining (score 0), 1–20% (score 1+), 21–50%
of positive cells (score 2+), and more than 50% of
positive cells (score 3+). The staining intensity was
scored on a scale as weak, moderate or strong.
Results
Clinical findings
Oral symptoms in cases of incomplete MRS [oligo and
monosymptomatic (CG)] were labial enlargement, oral
mucosal swelling, gingival erythematous lesions and
fissured tongue. One MRS patient demonstrated facial
nerve palsy. Patients with OCD differed from patients
with MRS for a cobblestone appearance and/or multiple
painful ulcers of the oral mucosa.
Histopathological study
On histopathological examination, mucosal specimens
from patients suffering from CG, MRS and OCD
showed essentially two patterns of inflammatory reac-
tions: (i) edematous/lichenoid which represents the first
phase of the inflammatory process in OFG and in OCD,
and (ii) granulomatous which represents the terminal
phase of the inflammatory process. The former was seen
in three out of four cases of CG, in three out of six MRS
cases and in three out of five OCD cases, and was
characterized by prominent subepithelial edema, in-
creased number of dilated lymphatic vessels (Figure 1)
and a moderate to marked inflammatory infiltrate in
lichenoid distribution. The infiltrate was mainly com-
posed of lymphocytes and histiocytes intermingled with
numerous plasma cells (Figure 2). The granulomatous
pattern of inflammation was observed in one CG case,
in three MRS cases and in two OCD cases, and was
characterized by the presence of a variable number of
non-caseating granulomas, composed of epithelioid
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histiocytes intermingled with giant cells, lymphocytes,
and plasma cells within the chorion (Figures 3 and 4).
Increased numbers of mastocytes were detected in both
edematous/lichenoid and granulomatous lesions.
Immunohistochemical analysis
Protease-activated receptor-1 immunohistochemical ex-
pression was confined to the cells’ cytoplasm, with
occasional peripheral membrane pattern, whereas eva-
luation of PAR-2 immunoreactions displayed predomi-
nantly cytoplasmic with occasional cell membrane and
nuclear staining. In normal oral mucosa, PAR-1 was
expressed in the basal and suprabasal epithelial kerati-
nocytes. PAR-1 positivity was also consistently observed
in the pericytes and endothelial cells decorating the
blood vessels. Scattered fibroblasts were also PAR-1
positive. PAR-2 immunoreactivity was predominantly
localized to the basal and suprabasal epithelial layers,
whereas the upper superficial layers were unstained.
Endothelial cells of the superficial dermal blood vessels,
fibroblasts, and mast cells also stained positive.
Figure 1 Edematous pattern in orofacial granulomatosis. Marked
subepithelial edema, increased number of dilated lymphatic vessels and
a slight inflammatory infiltrate within the chorion is observed
Figure 2 Lichenoid pattern in orofacial granulomatosis. Marked
inflammatory infiltrate, mainly composed of lymphocytes and
histiocytes in lichenoid distribution
Figure 3 Granulomatous pattern in orofacial granulomatosis. A
non-caseating granuloma is present in the subepithelial region
Figure 4 Granulomatous pattern in orofacial granulomatosis. Epithe-
lioid histiocytes intermingled with giant cells, lymphocytes, plasma
cells and scattered mastocytes are seen
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Results of the immunohistochemical analysis in OFG
patients are given in Table 1. Overall, PAR-1 and PAR-
2 expressions were related to the intensity of the
inflammatory infiltrate. PAR-1 positivity was mostly
observed in mononuclear inflammatory cells in lichenoid
and edematous lesions whereas a strong PAR-2
immunostaining was detected in the cell cytoplasm of
epithelioid histiocytes and giant cells in granulomatous
lesions, irrespective of the clinical features (OCD vs
MRS) (Figure 5). MMP-2 and MMP-9 staining was
observed in the cytoplasm of fibroblasts, vascular
endothelial cells and inflammatory cells. Stromal stain-
ing was poorly defined and gave the impression to be
predominantly present in the extra-cellular matrix.
MMPs expression was also seen, at varying frequencies
and intensities, in the overlying epithelium. In OFG
biopsies, MMP-2 and MMP-9 were expressed in the
inflammatory cells of the edematous/lichenoid lesions
and markedly overexpressed in granulomatous lesions,
especially MMP-9 (Figure 6). COX-1 was weakly and
variably expressed in both edematous/lichenoid and
granulomatous lesions while COX-2 was constantly and
markedly expressed in granulomatous lesions, indepen-
dently from the clinical features [OCD vs MRS (oligo
and monosymptomatic (CG)] (Figure 7).
Discussion
Our study shows that: (i) PAR-1 and PAR-2 are over-
expressed in biopsies taken from OFG patients; (ii) the
Table 1 PAR-1, PAR-2, MMP-2, MMP-9, COX-1, and COX-2 immunohistochemical expression in 13 cases of orofacial granulomatosis
No. Diagnosis Type of inflammation

























1 MRS Edematous-lichenoid 1+ 1+ 1+ 2+ 2+ 3+ 2+ 3+ 1+ 2+ 2+ 2+
2 MRS Edematous-lichenoid 1+ 1+ 1+ 1+ 2+ 2+ 2+ 2+ 1+ 2+ 2+ 3+
3 MRS Granulomatous 3+ 1+ 3+ 2+ 1+ 1+ 2+ 2+ 1+ 1+ 2+ 2+
4 MRS Edematous-lichenoid 3+ 1+ 2+ 3+ 2+ 2+ 3+ 3+ 2+ 2+ 3+ 3+
5 MRS Granulomatous 2+ 1+ 3+ 2+ 3+ 3+ 3+ 3+ 1+ 3+ 3+ 3+
6 CG Granulomatous 2+ 1+ 3+ 1+ 3+ 3+ 3+ 3+ 2+ 2+ 3+ 2+
7 CG Edematous-lichenoid 1+ 1+ 1+ 2+ 2+ 3+ 2+ 3+ 1+ 2+ 2+ 2+
8 CG Edematous-lichenoid 3+ 1+ 2+ 1+ 2+ 2+ 2+ 3+ 1+ 1+ 1+ 2+
9 Crohn Edematous-lichenoid 2+ 2+ 1+ 3+ 1+ 3+ 1+ 2+ 1+ 2+ 2+ 3+
10 Crohn Granulomatous 3+ 3+ 3+ 3+ 3+ 3+ 3+ 3+ 2+ 3+ 3+ 3+
11 Crohn Edematous-lichenoid 2+ 1+ 1+ 1+ 2+ 2+ 2+ 2+ 1+ 2+ 2+ 2+
12 Crohn Edematous-lichenoid 2+ 1+ 1+ 2+ 2+ 3+ 3+ 3+ 1+ 2+ 3+ 3+
13 Crohn Granulomatous 1+ 2+ 3+ 1+ 2+ 2+ 3+ 2+ 1+ 1+ 2+ 2+
MRS, Melkersson–Rosenthal syndrome; CG, cheilitis granulomatosa; Infl., inflammatory; Epit., epithelial; 1+, 1–20% of positive cells; 2+,
21–50% of positive cells; 3+, more than 51% of positive cells.
Figure 5 PAR-1 positivity is observed in
mononuclear inflammatory cells in lichenoid
and edematous lesions. Strong PAR-2
immunostaining is detected in the cytoplasm
of epithelioid histiocytes and giant cells in
granulomatous lesions
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intensity and distribution of receptor expression is
associated with the histopathological pattern (edema-
tous/lichenoid vs. granulomatous) but not to the clinical
type of the lesion (MRS vs. OCD); (iii) the intensity of
receptor expression is also related to the grade of the
inflammatory response; (iv) MMP-2, MMP-9, COX-2
are also upregulated in OFG biopsies. PAR-2 immu-
noreactivity was markedly overexpressed in granuloma-
tous lesions while immunostaining for PAR-1 was
mostly observed in the mononuclear cell inflammatory
component in early lichenoid/edematous lesions, in a
manner independent from the clinical diagnosis. Thus,
PARs overexpression seems to occur at the site of the
oral granulomatous inflammatory disorder, irrespective
from the lesion type: idiopathic vs secondary or localized
vs systemic.
The present immunohistochemical investigation
shows that PAR-1 and -2 are present on virtually all
the cells of oral tissues derived from OFG patients,
including inflammatory cells (monocytes-macrophages,
lymphocytes) that are resident in or recruited to the oral
tissues, surface epithelial cells, mast cells, vascular
Figure 6 MMP-2 and MMP-9 are expressed
in the inflammatory cells of edematous/liche-
noid lesions and markedly overexpressed in
granulomatous lesions, especially MMP-9
Figure 7 COX-1 is weakly and variably ex-
pressed in edematous/lichenoid lesions while
COX-2 is constantly and markedly expressed
in granulomatous lesions
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endothelial cells, and fibroblasts. All these cell types may
contribute to the process of inflammation in such a
microenvironment. A marked up-regulation of PAR-2
was demonstrated in macrophages localized within
granulomatous foci. Intense PAR-2 immunoreactivity
in these areas was, however, patchy in distribution,
indicating a mixed population of PAR-2-reactive cells. It
is not possible to determine which protease(s) activates
PARs in the context of OFG tissues. Factors of the
coagulation cascade may contribute to PARs activation
as proteases released from mast cells or proteases
originating from other cellular sources. Present findings
that a large number of mast cells were seen in both
edematous/lichenoid and granulomatous OFG lesions
suggest a major role of PAR-2 activating proteases, e.g.
tryptase, in OFG tissues.
We provided evidence for a simultaneous over-
expression of PARs, MMPs and COXs, suggesting that
these receptors and enzymes could synergistically con-
tribute to the proinflammatory mechanism of OFG.
MMP-2 and MMP-9 were found largely expressed by
the stromal fibroblasts as well as by inflammatory cells
recruited in oral tissues. However, because immunohis-
tochemistry cannot discriminate between latent and
activated forms of MMPs (Curran and Murray, 1999),
we cannot conclude that a significant MMP proteolytic
activity is present in the OFG tissue. A recent study has
proposed a role of PAR-2 in periodontitis in rats
through a mechanism involving prostaglandin release
and MMP-2 and MMP-9 activation (Holzhausen et al,
2005). Treatment with the PAR-2 agonist, SLIGRL-
NH2 when compared with the inactive peptide
LRGILS-NH2, increased alveolar bone destruction
and granulocytic infiltration in gingival tissues, and
caused significant over-expression of COX-1, COX-2,
MMP-2 and MMP-9 (Holzhausen et al, 2005). Evidence
for the involvement of MMPs and COXs in PAR-2
agonist-induced periodontitis was confirmed by a
reduced inflammatory response following doxycycline
(which inhibits MMP-2 and MMP-9 expression) and
indomethacin (which induces non-selective inhibition of
COX-1 and COX-2) administration (Holzhausen et al,
2005).
A possible interaction between the MMP family and
PARs has been recently proposed in diverse tumoral
models. Activation of PAR-1 or PAR-2 increased the
levels of MMP-2 and MMP-9 activity in prostate cancer
cell lines, favoring their potential metastatic role
(Wilson et al, 2004). More recent findings (Boire et al,
2005; Pei, 2005) have suggested that interstitial collage-
nase MMP-1, mainly secreted by peritumoral stromal
fibroblasts, functions as a protease agonist of PAR-1
cleaving and activating the receptor to promote cell
migration and metastasis. Further research will clarify
whether MMP-1 may contribute to PAR-1 activation
also in the context of inflammatory, non-tumoral,
conditions.
Overexpression of PARs in OCD is in line with the
previous observations indicating that PAR-1 expres-
sion is up-regulated in biopsies taken from patients
with inflammatory bowel diseases (IBD) (Vergnolle
et al, 2004). In the colon of IBD patients PAR-1 could
be activated not only by proteases from the coagula-
tion cascade, such as thrombin, factor Xa, or factor
VIIa, but also by bacterial proteases (Vergnolle et al,
2004). In the ileal and colonic mucosa of IBD patients,
an increased number of mast cells has been demon-
strated accompanied by elevated histamine and tryp-
tase levels, suggesting that tryptase, as PAR-2 agonist,
may be involved in the pathogenesis of IBD (He,
2004).
The present findings of PAR-1 and PAR-2 over-
expression related to the intensity and type of
inflammatory response support the hypothesis that
pharmacological blockade of PARs may be beneficial
in these types of chronic oral inflammatory disorders.
Because it is possible that PARs-induced oral inflamma-
tion involves prostaglandin release and MMP activa-
tion, also drugs that block these enzymatic activities
may contribute positively to the treatment of these
diseases.
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